How to Get Vyleesi (Bremelanotide) in Missouri

What Vyleesi Is and Why It Requires a Prescription

Vyleesi is the brand name for bremelanotide, a melanocortin receptor agonist approved by the FDA on June 21, 2019, specifically for acquired, generalized HSDD in premenopausal women. It is not an aphrodisiac and it is not indicated for men or postmenopausal women under the current label. Because the mechanism involves central nervous system melanocortin pathways, the FDA requires physician oversight, making it a Schedule-exempt prescription-only product with a specific patient selection process [1].

The RECONNECT trials were two identically designed, randomized, double-blind, placebo-controlled studies (Study 1, N=625; Study 2, N=642) that formed the basis of FDA approval. Women who received bremelanotide 1.75 mg subcutaneously reported a statistically significant increase in satisfying sexual events and a decrease in distress scores compared with placebo (P<0.001 for the co-primary endpoints in both studies) [2]. The FDA label notes that "bremelanotide demonstrated efficacy in the treatment of HSDD as measured by both co-primary endpoints in two randomized controlled trials" [1].

Bremelanotide works by activating melanocortin receptors (MC1R and MC4R) in the brain rather than acting peripherally like sildenafil. That central mechanism explains why the drug requires careful screening for uncontrolled hypertension: transient blood pressure increases of approximately 2 mmHg systolic and 1 mmHg diastolic occur in most users within 12 hours of dosing [1].

Missouri Telehealth Law and Bremelanotide Prescribing

Missouri permits telehealth prescribing of bremelanotide to new patients, provided the prescriber follows Missouri's standard of care requirements. Missouri Revised Statutes Section 191.1145 (the Show-Me State Telehealth Act, revised 2021) explicitly allows synchronous audio-video encounters to satisfy the examination requirement for prescription medications. No prior in-person visit is required as long as the clinical encounter meets documentation standards.

This matters for HSDD patients because sexual health concerns are among the most commonly undertreated conditions in primary care. A 2019 survey published in the Journal of Sexual Medicine estimated that 10% of U.S. premenopausal women meet diagnostic criteria for HSDD, yet fewer than 7% ever discuss the condition with a clinician [3]. Telehealth removes geographic and social barriers that are especially pronounced in Missouri's rural counties, where OB/GYN access is limited to roughly 38 of 114 counties [4].

Providers prescribing through telehealth in Missouri must hold a valid Missouri medical license (or a license in a compact state if Missouri participates in the relevant compact, which it does for the Interstate Medical Licensure Compact). Nurse practitioners and physician assistants with prescriptive authority granted by the Missouri State Board of Nursing or the State Board of Registration for the Healing Arts may also prescribe bremelanotide without a collaborative practice agreement under Missouri's 2019 NP prescribing law changes, provided they meet the relevant experience thresholds.

Step-by-Step: Getting a Bremelanotide Prescription in Missouri

The path from first question to first injection has four practical stages.

Stage 1: Find a qualified prescriber. Options include your existing OB/GYN or primary care physician, a sexual medicine specialist, or a telehealth platform operating in Missouri. When contacting a telehealth provider, confirm the prescriber holds an active Missouri license and that the platform can route the prescription to a Missouri-licensed pharmacy.

Stage 2: Complete the clinical intake. The prescribing visit typically runs 20 to 40 minutes. The clinician will review your menstrual status (bremelanotide is contraindicated in confirmed or suspected pregnancy), blood pressure history, cardiovascular risk factors, and current medications. Particular attention goes to any monoamine oxidase inhibitor (MAOI) use, as bremelanotide is contraindicated with MAOIs due to additive blood pressure effects [1]. The DSM-5 diagnostic criteria for HSDD require that low desire causes marked distress and has persisted for at least six months, so expect questions about symptom duration and impact on quality of life.

Stage 3: Prior authorization (if using commercial insurance). Missouri Medicaid does not cover bremelanotide for HSDD. Most commercial plans in Missouri require prior authorization before dispensing. The PA packet typically needs a DSM-5-aligned diagnosis code (F52.0, hypoactive sexual desire dysfunction), documentation of symptom duration exceeding six months, confirmation that the patient is premenopausal, a blood pressure reading below 130/80 mmHg at the time of prescribing, and, for many plans, a step-therapy note confirming that counseling or other interventions were considered. Approval timelines average 5, 10 business days through Missouri commercial insurers.

Stage 4: Dispensing and delivery. Once approved, the prescription can go to a retail pharmacy with bremelanotide stock, a specialty pharmacy, or a licensed 503A compounding pharmacy. Patients using manufacturer savings programs (Palatin Technologies has offered a savings card program reducing copays to as low as $99 per month for eligible commercially insured patients) should confirm current eligibility directly with the manufacturer before the prescription is sent.

Labs and Clinical Screening Before Your First Dose

No mandatory laboratory panel is required by the FDA label before initiating bremelanotide, but prudent clinical practice includes specific assessments. Baseline blood pressure measurement is the single most important screening step. The FDA label carries a warning against use in patients with known cardiovascular disease or uncontrolled hypertension [1]. A blood pressure reading <130/80 mmHg is the standard threshold most Missouri telehealth prescribers apply.

A urine pregnancy test is also standard practice. Bremelanotide is FDA Pregnancy Category X (it is listed as contraindicated in pregnancy under current labeling language). Missouri's 2019 telemedicine guidance recommends that pregnancy status be confirmed, either through self-reported last menstrual period or point-of-care testing, before a prescription is transmitted electronically.

Some clinicians add a basic metabolic panel and a thyroid-stimulating hormone (TSH) level to rule out hypothyroidism or adrenal insufficiency as reversible contributors to low desire. The Endocrine Society's 2019 clinical practice guideline on female sexual dysfunction notes that "thyroid disease should be excluded before attributing low desire solely to HSDD" [5]. That step adds roughly three to five business days if lab results are needed before prescribing.

The HealthRX clinical team uses the following intake framework for Missouri bremelanotide evaluations:

1. Blood pressure confirmed <130/80 mmHg (telehealth-compatible home monitoring with validated cuff accepted)
2. Pregnancy excluded by last menstrual period within 28 days or negative urine hCG
3. HSDD distress confirmed: Female Sexual Distress Scale-Revised (FSDS-R) score >11 at intake
4. MAOI use screened and ruled out
5. DSM-5 symptom duration confirmed >6 months
6. Cardiovascular risk stratification: no known CAD, uncontrolled HTN, or recent stroke

Patients who clear all six criteria are candidates for a same-visit prescription at telehealth appointments on the HealthRX platform.

503A Compounding Pharmacies in Missouri: What Patients Should Know

A 503A pharmacy is a traditional compounding pharmacy regulated primarily by state boards of pharmacy rather than under FDA's 503B outsourcing framework. Missouri's Board of Pharmacy licenses 503A pharmacies to compound patient-specific preparations when a commercial product is unavailable, inappropriate for the patient, or when cost creates a barrier.

Bremelanotide is commercially available as Vyleesi (Palatin/AMAG Pharmaceuticals), so 503A compounding of bremelanotide operates in a legal gray area under federal law. The FDA has not placed bremelanotide on its list of drugs that may not be compounded (the "negativelist"), but federal guidance suggests that compounding a commercially available drug requires a clinically significant reason, such as documented hypersensitivity to an excipient in the commercial formulation. Missouri's Board of Pharmacy has not issued a state-specific prohibition on compounding bremelanotide as of the date of this article's review [6].

Patients should ask any 503A pharmacy for their Missouri license number and request a Certificate of Analysis for the active pharmaceutical ingredient. Compounded bremelanotide is typically formulated as a subcutaneous injection at 10 mg/mL (1.75 mg per 0.175 mL dose), mirroring the Vyleesi auto-injector concentration. Pricing at Missouri 503A pharmacies generally ranges from $95, $175 for a four-dose vial, compared with a retail cash price of approximately $800, $1,000 for a single Vyleesi auto-injector.

How to Use Bremelanotide: Dosing and Administration

The FDA-approved dose is 1.75 mg subcutaneously in the abdomen or thigh, administered at least 45 minutes before anticipated sexual activity. The drug should not be used more than once within 24 hours, and the label recommends no more than one dose per day. Clinical trial data showed no benefit from using it more than eight times per month [1].

Most patients experience the peak desire-enhancing effect between 45 and 90 minutes after injection. The most common adverse effects observed in RECONNECT were nausea (40% of bremelanotide-treated patients vs. 1% placebo), flushing (20% vs. 2%), and injection-site reactions (13% vs. 7%) [2]. Nausea typically peaks at 30 to 60 minutes post-injection and resolves within 2 to 4 hours. Taking the injection on an empty stomach worsens nausea; eating a light meal 30 minutes before the injection is one mitigation strategy documented in the prescribing information [1].

The transient blood pressure increase is usually clinically insignificant in healthy patients but warrants monitoring in anyone with borderline hypertension. Patients should sit for 12 hours after dosing if they have a history of orthostatic hypotension. The label advises clinicians to "assess blood pressure before initiating treatment and to instruct patients to avoid using bremelanotide if blood pressure is elevated on the day of intended use" [1].

Insurance Coverage and Cost in Missouri

Missouri Medicaid categorically excludes bremelanotide from its preferred drug list. The state's Medicaid formulary covers GLP-1 receptor agonists only for type 2 diabetes, and that coverage logic does not extend to sexual dysfunction medications [7].

Commercial insurance coverage in Missouri varies by plan. A 2022 pharmacy benefit analysis by the Academy of Managed Care Pharmacy found that approximately 32% of U.S. commercial plans covered at least one FDA-approved female sexual dysfunction medication, with most requiring two levels of prior authorization [8]. Missouri-specific data from the Division of Insurance Regulation shows that the three largest commercial group plans in the state, covering roughly 2.1 million lives, all list bremelanotide as a Tier 4 or Tier 5 specialty drug with prior authorization requirements.

For patients paying cash, the manufacturer's savings card has historically allowed commercially insured patients to pay $99 per fill. Uninsured patients may qualify for the Palatin Technologies patient assistance program, which provides free medication to patients below 400% of the federal poverty level. Contact information for that program is available through the NeedyMeds database maintained at needymeds.org.

The most cost-effective path for uninsured Missouri patients who have a clinically compelling reason to avoid the commercial product (such as an excipient allergy) is a prescription written for compounded bremelanotide at a licensed Missouri 503A pharmacy, with estimated costs of $95, $175 per four-dose supply.

Transferring an Existing Vyleesi Prescription to Missouri

If you have an existing bremelanotide prescription from another state and have moved to Missouri, federal law permits a one-time transfer of a non-controlled prescription between licensed pharmacies in different states, as long as Missouri's Board of Pharmacy rules are met. Bremelanotide is not a controlled substance, so the transfer does not require DEA involvement.

Contact your current pharmacy and ask them to transfer the remaining refills electronically to a Missouri-licensed pharmacy of your choice. Missouri pharmacies accept electronic transfers under Missouri Code of State Regulations Title 20, Division 2220. If the original prescription was written by an out-of-state provider who is not licensed in Missouri and you are now a Missouri resident, that prescription may still be filled for its remaining refills, but a new prescription for subsequent fills will require a Missouri-licensed prescriber.

If you used a telehealth platform to get the original prescription, verify whether that platform has Missouri-licensed prescribers available for follow-up appointments. Most national telehealth platforms operating in Missouri can issue a Missouri-compliant renewal prescription at your next check-in visit.

What to Expect at Your Telehealth Visit

A telehealth appointment for bremelanotide in Missouri runs, on average, 25 minutes for new patients. The visit covers a sexual health history (including relationship context, hormonal history, and any prior treatments for low desire), a medication reconciliation focusing on antidepressants and MAOIs, and a blood pressure check that you perform at home with a validated automated cuff.

The Female Sexual Function Index (FSFI) is a validated 19-item questionnaire many Missouri telehealth providers send during intake. An FSFI desire subscale score of 3.3 or below is associated with HSDD in published validation studies [9]. Completing this before your visit can shorten the appointment and provides objective baseline documentation useful for insurance prior authorization.

After the visit, the clinician sends a prescription electronically to your preferred pharmacy. Missouri law permits e-prescribing of non-controlled substances, and most telehealth platforms integrate directly with major pharmacy networks. Standard shipping from a specialty or compounding pharmacy runs three to five business days within Missouri.

Specific Considerations for Rural Missouri Patients

Approximately 38% of Missouri's population lives in rural or micropolitan areas where OB/GYN and sexual medicine specialists are scarce [4]. The most practical route for rural patients is a telehealth visit with a platform that employs Missouri-licensed prescribers and partners with a mail-order pharmacy or a regional 503A compounder capable of shipping within Missouri.

Missouri's telehealth parity law (SB 220, 2021) requires commercial insurers to reimburse telehealth visits at the same rate as in-person visits for covered services. A telehealth consultation for HSDD would typically be billed under CPT code 99213 or 99214 (established or new patient office visit, low-to-moderate complexity), both of which are covered services under most commercial plans. That coverage applies to the visit even when the resulting prescription is not covered.

Rural patients using a home blood pressure cuff should confirm the device is validated by the European Society of Hypertension's validation list (dableducational.org) or carries AHA recommended designation, since inaccurate readings can either block access to the medication inappropriately or, more seriously, miss a contraindicated elevation before dosing.

A blood pressure at or above 130/80 mmHg on the day you plan to use bremelanotide means you should not inject that day and should contact your prescriber to discuss whether antihypertensive management is needed before restarting [1].